Adicet Bio Sets 2024 Goals: Advancing Allogeneic Gamma Delta T Cell Therapies in Oncology and Autoimmune
Portfolio Pulse from Benzinga Newsdesk
Adicet Bio, Inc. (NASDAQ:ACET) aims to advance its pipeline of allogeneic gamma delta T cell therapies in 2024, focusing on oncology and autoimmune diseases. The FDA cleared an IND for ADI-001 in lupus nephritis, with a Phase 1 trial expected in Q2 2024. In hematologic malignancies, ADI-001 showed promising results in MCL patients, and a clinical update is anticipated in the second half of 2024. The company also plans to file an IND for ADI-270, targeting renal cell carcinoma, in Q2 2024. Adicet Bio's cash runway is projected to last into the second half of 2025.
January 04, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adicet Bio, Inc. is advancing its allogeneic gamma delta T cell therapies, with a cleared IND for ADI-001 in lupus nephritis and a Phase 1 trial set for Q2 2024. Promising results in MCL patients and an IND filing for ADI-270 in renal cell carcinoma are expected in 2024.
The positive regulatory developments and promising clinical trial results for Adicet Bio's therapies are likely to be viewed favorably by investors, potentially leading to a positive short-term impact on ACET's stock price. The focus on areas with high unmet medical needs and the company's cash runway extending into the second half of 2025 provide a solid foundation for continued development and potential value creation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100